Showing 241 - 260 results of 25,539 for search '(( 50 ng decrease ) OR ((( 50 ((nn decrease) OR (a decrease)) ) OR ( a point decrease ))))', query time: 0.61s Refine Results
  1. 241
  2. 242

    Economic review of point-of-care EEG by Adam Green (14072544)

    Published 2023
    “…<p><b>Aims:</b> Point-of-care electroencephalogram (POC-EEG) is an acute care bedside screening tool for the identification of nonconvulsive seizures (NCS) and nonconvulsive status epilepticus (NCSE). …”
  3. 243
  4. 244
  5. 245
  6. 246
  7. 247
  8. 248

    FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma. by Laura L. Stafman (6577184)

    Published 2019
    “…There was a trend toward decreased Ki67 staining in FTY720-treated tumors (p = 0.29). …”
  9. 249
  10. 250
  11. 251
  12. 252

    NatB inactivation decreased the level of MAPK and proposed model of EGFR/MAPK signaling regulation by NatB and the N-end rule pathways. by Zhentao Sheng (107495)

    Published 2020
    “…<p>(A-B) <i>psid-D1</i> (A) or <i>psid-D4</i> (B) clones in 3rd instar fat body, which were marked by GFP expression (pointed by arrowheads), showed decreased MAPK levels (anti-MAPK staining, red). …”
  13. 253
  14. 254
  15. 255
  16. 256
  17. 257
  18. 258
  19. 259
  20. 260

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”